US20130150550A1 - Antibiotic-Bound Poly(Caprolactone) Polymer - Google Patents
Antibiotic-Bound Poly(Caprolactone) Polymer Download PDFInfo
- Publication number
- US20130150550A1 US20130150550A1 US13/367,965 US201213367965A US2013150550A1 US 20130150550 A1 US20130150550 A1 US 20130150550A1 US 201213367965 A US201213367965 A US 201213367965A US 2013150550 A1 US2013150550 A1 US 2013150550A1
- Authority
- US
- United States
- Prior art keywords
- caprolactone
- antibiotic
- polymerization
- lactone
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *OC(=O)CC1CCOC(=O)CC1 Chemical compound *OC(=O)CC1CCOC(=O)CC1 0.000 description 7
- XNELFFKVZBPKSF-UHFFFAOYSA-N C=C(C)CC1CCOC(=O)CC1 Chemical compound C=C(C)CC1CCOC(=O)CC1 XNELFFKVZBPKSF-UHFFFAOYSA-N 0.000 description 1
- BUVUMWWIMWGGMJ-UHFFFAOYSA-N C=C(CC1CCOC(=O)CC1)C1=CC=CC=C1.C=O Chemical compound C=C(CC1CCOC(=O)CC1)C1=CC=CC=C1.C=O BUVUMWWIMWGGMJ-UHFFFAOYSA-N 0.000 description 1
- NXWSAXZJNOVKRQ-UHFFFAOYSA-N C=CC(=O)OC(C)(C)C.CC(C)(C)OC(=O)C=C1CCC2(CC1)OCCO2.CC(C)(C)OC(=O)CC1CCC(=O)CC1.CC(C)(C)OC(=O)CC1CCC2(CC1)OCCO2.CC(C)(C)OC(=O)CC1CCOC(=O)CC1.O=C1CCC2(CC1)OCCO2 Chemical compound C=CC(=O)OC(C)(C)C.CC(C)(C)OC(=O)C=C1CCC2(CC1)OCCO2.CC(C)(C)OC(=O)CC1CCC(=O)CC1.CC(C)(C)OC(=O)CC1CCC2(CC1)OCCO2.CC(C)(C)OC(=O)CC1CCOC(=O)CC1.O=C1CCC2(CC1)OCCO2 NXWSAXZJNOVKRQ-UHFFFAOYSA-N 0.000 description 1
- FIWAIWHVKXLNPU-UHFFFAOYSA-N C=CC(=O)OC(C)(C)C.CC(C)(C)OC(=O)CBr.CCC(=O)OC(C)(C)C.[Br-] Chemical compound C=CC(=O)OC(C)(C)C.CC(C)(C)OC(=O)CBr.CCC(=O)OC(C)(C)C.[Br-] FIWAIWHVKXLNPU-UHFFFAOYSA-N 0.000 description 1
- KRRUVNDIJDBEQG-UHFFFAOYSA-N CC(C)(C)OC(=O)CC1CCOC(=O)CC1 Chemical compound CC(C)(C)OC(=O)CC1CCOC(=O)CC1 KRRUVNDIJDBEQG-UHFFFAOYSA-N 0.000 description 1
- AETFBTIQANKDII-UHFFFAOYSA-N CC(C)(C)OC(=O)CC1CCOC(=O)CC1.O=C1CCCCCO1.[H]OCCCCCC(=O)OCCC(CCC(=O)CO)CC(=O)OC(C)(C)C Chemical compound CC(C)(C)OC(=O)CC1CCOC(=O)CC1.O=C1CCCCCO1.[H]OCCCCCC(=O)OCCC(CCC(=O)CO)CC(=O)OC(C)(C)C AETFBTIQANKDII-UHFFFAOYSA-N 0.000 description 1
- UCMMFCNLBFGBCQ-UHFFFAOYSA-N CCOC(=O)C=C1CCC2(CC1)OCCO2.CCOC(=O)CC1CCC2(CC1)OCCO2.O=C(CC1CCC2(CC1)OCCO2)OCC1=CC=CC=C1.O=C(O)CC1CCC2(CC1)OCCO2.O=C1CCC(CC(=O)OCC2=CC=CC=C2)CC1.O=C1CCC(CC(=O)OCC2=CC=CC=C2)CCO1.O=C1CCC2(CC1)OCCO2 Chemical compound CCOC(=O)C=C1CCC2(CC1)OCCO2.CCOC(=O)CC1CCC2(CC1)OCCO2.O=C(CC1CCC2(CC1)OCCO2)OCC1=CC=CC=C1.O=C(O)CC1CCC2(CC1)OCCO2.O=C1CCC(CC(=O)OCC2=CC=CC=C2)CC1.O=C1CCC(CC(=O)OCC2=CC=CC=C2)CCO1.O=C1CCC2(CC1)OCCO2 UCMMFCNLBFGBCQ-UHFFFAOYSA-N 0.000 description 1
- JUEYISZXAXVKKD-YKMSUXHJSA-N COCCCCCC(=O)OCCC(CCC(C)=O)CC(=O)O.COCCCCCC(=O)OCCC(CCC(C)=O)CC(=O)OC1C(=O)N(SC)[C@H]1C1=CC=CC=C1Cl.COCCCCCC(=O)OCCC(CCC(C)=O)CC(=O)OCC1=CC=CC=C1.CSN1C(=O)[C@H](O)[C@@H]1C1=C(Cl)C=CC=C1 Chemical compound COCCCCCC(=O)OCCC(CCC(C)=O)CC(=O)O.COCCCCCC(=O)OCCC(CCC(C)=O)CC(=O)OC1C(=O)N(SC)[C@H]1C1=CC=CC=C1Cl.COCCCCCC(=O)OCCC(CCC(C)=O)CC(=O)OCC1=CC=CC=C1.CSN1C(=O)[C@H](O)[C@@H]1C1=C(Cl)C=CC=C1 JUEYISZXAXVKKD-YKMSUXHJSA-N 0.000 description 1
- BRCAERHHIKXXKC-UHFFFAOYSA-N COCCCCCC(=O)OCCC(CCC(C)=O)CC(=O)OCC1=CC=CC=C1.O=C1CCC(CC(=O)OCC2=CC=CC=C2)CCO1.O=C1CCCCCO1 Chemical compound COCCCCCC(=O)OCCC(CCC(C)=O)CC(=O)OCC1=CC=CC=C1.O=C1CCC(CC(=O)OCC2=CC=CC=C2)CCO1.O=C1CCCCCO1 BRCAERHHIKXXKC-UHFFFAOYSA-N 0.000 description 1
- HNFVZCXVKQGXMC-PCHQZIJMSA-N CSN1C(=O)C(OC(=O)CC2CCOC(=O)CC2)[C@H]1C1=C(Cl)C=CC=C1 Chemical compound CSN1C(=O)C(OC(=O)CC2CCOC(=O)CC2)[C@H]1C1=C(Cl)C=CC=C1 HNFVZCXVKQGXMC-PCHQZIJMSA-N 0.000 description 1
- BZJXXUGBFNMNQD-CBFLNKQBSA-N CSN1C(=O)C(OC(=O)CC2CCOC(=O)CC2)[C@H]1C1=C(Cl)C=CC=C1.CSN1C(=O)[C@H](O)[C@@H]1C1=C(Cl)C=CC=C1.O=C(O)CC1CCOC(=O)CC1.O=C1CCC(CC(=O)OCC2=CC=CC=C2)CCO1 Chemical compound CSN1C(=O)C(OC(=O)CC2CCOC(=O)CC2)[C@H]1C1=C(Cl)C=CC=C1.CSN1C(=O)[C@H](O)[C@@H]1C1=C(Cl)C=CC=C1.O=C(O)CC1CCOC(=O)CC1.O=C1CCC(CC(=O)OCC2=CC=CC=C2)CCO1 BZJXXUGBFNMNQD-CBFLNKQBSA-N 0.000 description 1
- IJFGUGSBFJUDCO-UHFFFAOYSA-N NOC(CC(CC1)CCOC1=O)=O Chemical compound NOC(CC(CC1)CCOC1=O)=O IJFGUGSBFJUDCO-UHFFFAOYSA-N 0.000 description 1
- INLYFDIWZSKFRH-UHFFFAOYSA-N O=C1CCC(CC(=O)OCC2=CC=CC=C2)CCO1 Chemical compound O=C1CCC(CC(=O)OCC2=CC=CC=C2)CCO1 INLYFDIWZSKFRH-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/04—Seven-membered rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyesters Or Polycarbonates (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This divisional application claims priority to U.S. Non-Provisional Application Ser. No. 11/746,706 filed on May 10, 2007 and U.S. Provisional Application No. 60/747,061 filed on May 11, 2006, entitled “Antibiotic-Bound Poly(Caprolactone) Polymer”.
- This invention was made with Government support under Grant No. RO1 A1 51351 awarded by the National Institutes of Health. The Government has certain rights in the invention.
- This invention relates to attaching one or more bioactive molecules to the same polymer, and also for attachment before or after polymerization
- The delivery of water-insoluble drugs to targets within the human body is a challenge that presently places strict limitations on what drugs can be applied clinically. The need for methods which overcome this is of high priority in the development of new therapeutics for treatment of human disease.
- The development of antibiotics for control of pathogenic bacteria has been of pressing need in this era of drug resistant infections. N-Methylthiolated b-lactams have been identified as a new family of antibacterial agents active against Staphylococcus bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). (See Turos, E.; Konaklieva, M. I.; Ren, R. X. F.; Shi, H.; Gonzalez, J.; Dickey, S.; Lim, D. Tetrahedron 2000, 56, 5571; Bart Heldreth, Timothy E. Long, Seyoung Jang, Suresh K. R. Guntireddygari, Edward Turos, Sonja Dickey, Daniel V. Lim, “N-Thiolated b-Lactam Antibacterials: Effects of the N-Organothio Substituent on anti-MRSA Activity,” Bioorganic and Medicinal Chemistry 14, 3775-3784 (2006); and Edward Turos, Jeung-Yeop Shim, Yang Wang, Kerriann Greenhalgh, G. Suresh Kumar Reddy, Sonja Dickey, Daniel V. Lim, “Antibiotic-Conjugated Polyacrylate Nanoparticles: New Opportunities for Development of Anti-MRSA Agents,” Bioorganic and Medicinal Chemistry Letters 16, in press (2006); which are incorporated herein by reference).
- The compounds have also displayed promising anticancer properties. These lactams exert their growth inhibitory effects on bacteria through a mode of action that is distinctively different to that of other b-lactam antibiotics, and possess structure-activity patterns unlike those already mapped for other b-lactam antibacterials such as the penicillins. One of the major limitations in the potential application of these N-thiolated b-lactam compounds, however, is their exceedingly low water solubility.
- Drug delivery vehicles such as liposomes and gold nanoparticles have been developed to improve bioavailability, efficacy, and specificity of pharmaceutical compounds, particularly for anticancer agents, but nanoparticles have received surprisingly little attention in the antibiotic and infectious disease area. Some of the few notable examples have included antibiotic-encapsulated polymeric nanoparticles and liposomes, biodegradable nanospheres and surface-coated gold and silver nanoparticles.
- In one embodiment, the invention provides an effective drug delivery platform that would enhance the water solubility of the lactams, without sacrificing inherent bioactivity.
- In another embodiment, the invention provides for the development of antibacterial polyacrylate nanoparticles based on well-precedented emulsion polymerization procedures.
- This invention addresses this need, and demonstrates the use of antibiotic-bound poly (caprolactone) polymers as anti-infective materials for biomedical applications in the prevention of bacterial infections.
- In a first embodiment, the invention includes a functionalized compound comprising at least one caprolactone ring with an appended functional group. A plurality of methylene groups act as a spacer between the lactone ring and the functional group. In a preferred embodiment, the functional group is an antibiotic, such as a N-thiolated β-lactam. The functional group is preferably covalently bonded.
- In an alternate embodiment, a method is provided for producing the functionalized compound of the previous embodiment. The method includes providing a at least one caprolactone ring with a protecting group spaced apart from the caprolactone ring by a plurality of methylene groups. The protecting group is then cleaved from the caprolactone ring and replaced by bonding a functional group to the caprolactone ring. Illustrative reagents for cleaving the protecting group include 10% pd/C as a catalyst in the presence of H2(g) and ethyl acetate (EtOAc). The protecting group is selected from the group consisting of alcohol protecting groups, amine protecting groups, carbonyl protecting groups and carboxyl protecting groups. In a preferred embodiment, the protecting group is selected for the group consisting of a benzel ester and a tert-butyl ester. As with the previous embodiment, the functional group is an antibiotic such as a N-thiolated β-lactam.
- In another embodiment, the invention includes the compound represented by the formula:
- or a pharmaceutically acceptable salt or ester thereof, wherein is selected from the group consisting of water-insoluble drugs, antibiotics, lactams, β-lactams, N-thiolated β-lactams and protecting groups. The protecting group is selected from the group consisting of alcohol protecting groups, amine protecting groups, carbonyl protecting groups and carboxyl protecting groups.
- In yet another embodiment, the invention includes the compound represented by the formula:
- or a pharmaceutically acceptable salt or ester thereof.
- In another embodiment, the invention includes the compound represented by the formula:
- or a pharmaceutically acceptable salt or ester thereof.
- In still another embodiment, the invention includes the compound represented by the formula:
- or a pharmaceutically acceptable salt or ester thereof.
- For a fuller understanding of the nature and objects of the invention, reference should be made to the following detailed description, taken in connection with the accompanying drawings, in which:
-
FIG. 1 shows the polymerization of a caprolactone monomer to polycaprolactone (PCL). -
FIG. 2 shows the functionalized caprolactone polymer can be used for covalent binding of drug molecules. -
FIG. 3 shows examples of functionalized caprolactones from the literature. -
FIG. 4 shows the functionalized lactone of present invention. -
FIG. 5A shows drug appendage before polymerization. -
FIG. 5B shows drug appendage after polymerization. -
FIG. 6 shows lactone resynthesis. -
FIG. 7 shows ylide synthesis. -
FIG. 8 is an image showing results of biological testing of the lactam-containing monomer vs. MSSA. -
FIG. 9 demonstrates the anti-Bacillus activity of the β-lactam containing copolymer. -
FIG. 10 shows the invention employing an alternate carboxyl protecting group. - In the following detailed description of the preferred embodiments, reference is made to the accompanying drawings, which form a part hereof, and within which are shown by way of illustration specific embodiments by which the invention may be practiced. It is to be understood that other embodiments may be utilized and structural changes may be made without departing from the scope of the invention.
- N-Thiolated β-Lactams
- New family of anti-MRSA and anti-Bacillus agents that have recently been reported by our laboratory. Extensive SAR studies have shown that changing the N-thioalkyl substituent has a large effect on the bioactivity and that changes at the other positions of the ring exert a more subtle effect. Recent research in our group has been focused on covalent attachment of these and other antibiotics to polymers for drug, delivery and for new biomaterials.
- As used herein, the term “drug” to any therapeutic or prophylactic agent other than food which is used in the prevention, diagnosis, alleviation, treatment, or cure of disease in man or animal.
- As used herein, the term “antibiotic” refers to any natural, synthetic, and semi-synthetic compound that has been identified as possessing antibacterial, antifungal, antiviral, or antiparasitic activity.
- Polycaprolactones
- Polycaprolactone (PCL) is a biodegradable polyester which can be prepared by ring opening polymerization of ε-caprolactone using a catalyst such as stannous octanoate, as shown in
FIG. 1 . PCL is degraded by hydrolysis of its ester linkages in physiological conditions (such as in the human body) and is therefore useful as a biomaterial. PCL has been approved by the Food and Drug Administration (FDA) for use in the human body as (for example) a suture (sold under the brand name Monocryl™ or generically). In particular, PCL has been used in long term implantable devices, owing to its degradation which is relatively slow. (See V. R. Sinha, K. Bansal, R. Kaushik, R. Kumria and A. Trehan; Poly-ε-caprolactone microspheres and nanospheres: an overview, International Journal of Pharmaceutics, Volume 278, Issue 1, 18 Jun. 2004, Pages 1-23; which is incorporated herein by reference.) - The characteristics of PCL make it useful as a delivery mechanism for antibiotics. For example PCL is biodegradable (bulk hydrolysis of ester bonds), the byproducts of degradation are non-toxic (biocompatible), it is FDA approved and displays high permeability to many drugs. Therefore, the invention provides a functionalized caprolactone polymer can be used for covalent binding of drug molecules (
FIG. 2 ). - The functionalized caprolactones of the prior art (Detrembleur et al Macromolecules, 2000, 33, 14-18 and Trollsas et at Macromolecules, 2000, 33, 4619-4627) are shown in
FIG. 3 . In contrast, the functionalized lactone 10 of present invention is shown inFIG. 4 . Lacton 10 comprises at least one lactone ring 12, functional group 16 and at least one spacer 14. As it can be seen, functional group 16 is placed away from site of polymerization. Moreover, an additional methylene spacer 14 between functional group 16 and lactone ring 12 enhances further functionalization. - In another embodiment, the invention provides a method of producing an antibiotic-conjugated functionalized caprolactone (
FIG. 5A andFIG. 5B ). In Step 1 includes providing a caprolactone comprising lactone ring 12, methylene spacer 14 and protecting group 18. In Step 2, protecting group 18 is cleaved, preferably under mild conditions. Finally, in Step 3, drug ofinterest 20 is covalently bonded to the finished compound.FIG. 5A illustrates the method of appending a drug of interest to the functionalized lactone before polymerization.FIG. 5B illustrates the method of appending a drug of interest to the functionalized lactone after polymerization. Lactone retrosynthesis is shown inFIG. 6 and Ylide synthesis is shown inFIG. 7 . - The following represents an embodiment of the invention wherein 1,4-dioxaspiro[4.5]decan-8-one is used to synthesize a functionalized lactone bearing a pendent benzyl ester as the protecting group.
- Reagents and conditions: (a) 2 eq. ylide, C6H6, 12 h, reflux; (b) 60 psi H2(g), cat. 10% Pd/C, MeOH, 12 h; (c) 3LiOH, MeOH, 12 h, rt; 1M HCl; (d) 3K2CO3, 1.1 BnBr, MeCN, 12 h, reflux; (e) 70% AcOH, 12-24 h, rt; (f) 1.5mCPBA, CHCl3, 3-5 h, reflux.
- Next the functionalized lactone is coupled with an antibiotic, here N-thiolated β-lactam, after deprotection of benzyl ester.
FIG. 8 shows the results of biological testing of the lactam-containing monomer vs. MSSA. - Reagents and conditions: (a) cat. 10% Pd/C, 60 psi H2(g), EtOAc, 12 h; (b) 1.5 eq. EDCl, cat. DMAP, dry CH2Cl2, 12 h, rt.
- In another embodiment, the invention provides a PCL derived from copolymerization of a functionalized lactone monomer with caprolactone. Copolymers containing 10%, 15%, 20%, 25% and 30% of the substituted lactone were prepared and characterized by TLC, 1H, NMR, 13C NMR and MALDI-TOF. The Copolymers displayed low molecular, between about 1000 and 4000.
- Deprotection of the copolymer and coupling with the antibiotic, β-lactam, is shown below and was achieved using the following reagents and conditions: (a) cat. 10% Pd/C, H2(g), EtOAc, 12-24 h. (b) 15 EDCI, cat. DMAP, dry CH2Cl2, 12 h. rt. The antibiotic activity of the completed PCL against Bacillus is shown in
FIG. 9 . - In yet another embodiment, the functionalized lactone comprises a carboxyl protecting group, as shown in
FIG. 10 . Ylide synthesis is shown below using the reagents and conditions: (a) PPh3, C6H6, 12 h, rt; (b) 20% NaOH(aq), 5 h, rt. - The following demonstrates the synthesis of lactone bearing pendant tert-butyl ester using the reagents and conditions: (a) 1.5 eq. ylide C6H6. 12 h, reflux, (b) H2(g), cat. 10% Pd/C, EtOAC, 24 h; (c) 0.1 eq. I2, dry acetone, 1 hr, rt; (d) 1.5mCPBA CHCl3, 3 h, reflux.
- Copolymerization with caprolactone was achieved as shown below. Copolymers containing 10%, and 20% of the substituted lactone were prepared and characterized by TLC, 1H NMR and 13C NMR.
- Functional caprolactone monomers have been synthesized and characterized. The monomers were further copolymerized with caprolactone. Caprolactone monomers and polymers with covalently bound N-thiolated β-lactams have been prepared and shown to possess bioactivity against MSSA and Bacillis respectively.
- It will be seen that the advantages set forth above, and those made apparent from the foregoing description, are efficiently attained and since certain changes may be made in the above construction without departing from the scope of the invention, it is intended that all matters contained in the foregoing description or shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.
- It is also to be understood that the following claims are intended to cover all of the generic and specific features of the invention herein described, and all statements of the scope of the invention which, as a matter of language, might be said to fall therebetween. Now that the invention has been described,
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/367,965 US8470958B1 (en) | 2006-05-11 | 2012-02-07 | Antibiotic-bound poly(caprolactone) polymer |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74706106P | 2006-05-11 | 2006-05-11 | |
US11/746,704 US8110678B2 (en) | 2006-05-11 | 2007-05-10 | Antibiotic-bound poly(caprolactone) polymer |
US13/367,965 US8470958B1 (en) | 2006-05-11 | 2012-02-07 | Antibiotic-bound poly(caprolactone) polymer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/746,704 Division US8110678B2 (en) | 2006-05-11 | 2007-05-10 | Antibiotic-bound poly(caprolactone) polymer |
Publications (2)
Publication Number | Publication Date |
---|---|
US20130150550A1 true US20130150550A1 (en) | 2013-06-13 |
US8470958B1 US8470958B1 (en) | 2013-06-25 |
Family
ID=38685905
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/746,704 Expired - Fee Related US8110678B2 (en) | 2006-05-11 | 2007-05-10 | Antibiotic-bound poly(caprolactone) polymer |
US13/367,965 Expired - Fee Related US8470958B1 (en) | 2006-05-11 | 2012-02-07 | Antibiotic-bound poly(caprolactone) polymer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/746,704 Expired - Fee Related US8110678B2 (en) | 2006-05-11 | 2007-05-10 | Antibiotic-bound poly(caprolactone) polymer |
Country Status (2)
Country | Link |
---|---|
US (2) | US8110678B2 (en) |
WO (1) | WO2007133706A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005020933A2 (en) * | 2003-09-02 | 2005-03-10 | University Of South Florida | Nanoparticles for drug-delivery |
US8722937B2 (en) | 2006-02-27 | 2014-05-13 | University Of South Florida | Asymmetric disulfides and aryl-alkyl disulfides as anti-bacterial agents |
WO2008033278A1 (en) * | 2006-09-13 | 2008-03-20 | University Of South Florida | Heterosubstituted n-thiolated beta-lactam compounds and methods of use |
GB2463861B (en) * | 2008-09-10 | 2012-09-26 | Univ Manchester | Medical device |
US10973775B2 (en) * | 2017-09-22 | 2021-04-13 | University Of Manitoba | Antibacterial nanofiber |
US10828371B2 (en) | 2017-11-08 | 2020-11-10 | International Business Machines Corporation | Multifunctionalized bioactive polycaprolactone |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6703628A (en) * | 1966-03-25 | 1967-09-26 | ||
US5025025A (en) * | 1989-06-28 | 1991-06-18 | Ciba-Geigy Corporation | (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity |
JPH0816160B2 (en) * | 1990-01-25 | 1996-02-21 | 関西ペイント株式会社 | Resin curing method |
IT1264607B1 (en) * | 1993-06-15 | 1996-10-04 | Caffaro Spa Ind Chim | PROCEDURE FOR THE PRODUCTION OF AN ALIPHATIC-FUNCTIONALIZED CARBOXYLIC ACID AND INTERMEDIATES OF THIS PROCEDURE INCLUDING-2-OXEPANONE-7 |
ES2303337T3 (en) * | 1995-01-20 | 2008-08-01 | G.D. Searle Llc | INHIBITORS OF PROTEASA RETROVIRAL DE BIS-HIDROXIETILAMINO SULFONAMIDA. |
US5801224A (en) * | 1996-04-26 | 1998-09-01 | Board Of Trustees Operating Michigan State University | Bulk reactive extrusion polymerization process producing aliphatic ester polymer compositions |
TWI331526B (en) * | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
-
2007
- 2007-05-10 US US11/746,704 patent/US8110678B2/en not_active Expired - Fee Related
- 2007-05-11 WO PCT/US2007/011454 patent/WO2007133706A2/en active Application Filing
-
2012
- 2012-02-07 US US13/367,965 patent/US8470958B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8470958B1 (en) | 2013-06-25 |
WO2007133706A3 (en) | 2008-11-27 |
US20070265243A1 (en) | 2007-11-15 |
WO2007133706A2 (en) | 2007-11-22 |
US8110678B2 (en) | 2012-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8470958B1 (en) | Antibiotic-bound poly(caprolactone) polymer | |
CA2927832C (en) | Cyclodextrin-containing polymer-therapeutic agent conjugates and their use | |
US20200046845A1 (en) | Cyclodextrin-based polymers for therapeutic delivery | |
Ghalia et al. | Biodegradable poly (lactic acid)-based scaffolds: synthesis and biomedical applications | |
Rodriguez-Galan et al. | Degradable poly (ester amide) s for biomedical applications | |
EP0923566B1 (en) | High molecular weight polymer-based prodrugs | |
US7776814B2 (en) | Tubulysin conjugates | |
Ricapito et al. | Synthetic biomaterials from metabolically derived synthons | |
CA2440394C (en) | Biodegradable copolymers linked to segment with a plurality of functional groups | |
CN105358146B (en) | For delivering the polymer conjugate of bioactivator | |
US11591443B2 (en) | Polycarbonate containing compounds and methods related thereto | |
AU2002248535A1 (en) | Biodegradable copolymers linked to segment with a plurality of functional groups | |
US10113033B2 (en) | Polymer conjugate for delivery of a bioactive agent | |
NZ547668A (en) | Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives | |
KR20110091854A (en) | Biodegradable polymer-bioactive moiety conjugates | |
Varghese et al. | Beyond nylon 6: polyamides via ring opening polymerization of designer lactam monomers for biomedical applications | |
Lu et al. | Immobilized Candida antarctica lipase B catalyzed synthesis of biodegradable polymers for biomedical applications | |
CN101215377A (en) | Aliphatic polyester-polyamino acid Y-type three-arm block copolymers and synthetic method thereof | |
CN106336501B (en) | Containing sugared amphipathic nature block polymer and preparation method thereof | |
CN104203255A (en) | Cyclodextrin-based polymers for therapeutic delivery | |
CN100334081C (en) | 5-acrylic oxo-trimethylene carbonate and its preparation and use | |
CN1844192A (en) | Synthesis of ABA polypeptide -b- polytetrahydrofuran-b-polypeptide triblock copolymer | |
Turos et al. | Antibiotic-bound poly (caprolactone) polymer | |
KR100752702B1 (en) | Biodegradable polymer nanoparticles and method for preparing the same | |
JPH06256220A (en) | Polymer for drug-carrier |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF SOUTH FLORIDA;REEL/FRAME:028003/0232 Effective date: 20120403 |
|
AS | Assignment |
Owner name: UNIVERSITY OF SOUTH FLORIDA, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TUROS, EDWARD;LESLIE, MICHELLE;SIGNING DATES FROM 20120208 TO 20120410;REEL/FRAME:028149/0122 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF SOUTH FLORIDA;REEL/FRAME:031579/0872 Effective date: 20131003 |
|
FEPP | Fee payment procedure |
Free format text: PATENT HOLDER CLAIMS MICRO ENTITY STATUS, ENTITY STATUS SET TO MICRO (ORIGINAL EVENT CODE: STOM); ENTITY STATUS OF PATENT OWNER: MICROENTITY |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
CC | Certificate of correction | ||
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: MICROENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: MICROENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20210625 |